Search research articles
Contact Us
Filters
Showing results (61-70 of 85) with videos related to
Page
of 9
Sort By:
Alimentary Pharmacology & Therapeutics
|
December 31, 2021
Letter: evaluation and proposed reclassification of HCC prediction model of Tahata et al. in chronic hepatitis C genotype 4 patient. Authors' reply
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Alimentary Pharmacology & Therapeutics
|
October 7, 2021
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Cancers
|
January 21, 2023
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
Takayuki Matsumae, Takahiro Kodama, Yuki Tahata, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
December 12, 2022
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis
Yuki Tahata, Ryotaro Sakamori, Kazuki Maesaka, et al.
Scientific Reports
|
January 31, 2017
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment
Yugo Kai, Hayato Hikita, Naoki Morishita, et al.
Journal of Gastroenterology
|
September 15, 2012
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines
Naoki Harada, Naoki Hiramatsu, Tsugiko Oze, et al.
Digestive Diseases and Sciences
|
December 16, 2022
Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
June 24, 2022
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 6, 2016
Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection
Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, et al.
BMC Gastroenterology
|
May 1, 2026
Improvement of hepatic reserve and changes in liver and spleen volume after balloon-occluded retrograde transvenous obliteration
Kazuma Shinkai, Ryotaro Sakamori, Ryoko Yamada, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 85) with videos related to
Sort By:
Page
of 9
Alimentary Pharmacology & Therapeutics
|
December 31, 2021
Letter: evaluation and proposed reclassification of HCC prediction model of Tahata et al. in chronic hepatitis C genotype 4 patient. Authors' reply
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Alimentary Pharmacology & Therapeutics
|
October 7, 2021
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Cancers
|
January 21, 2023
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
Takayuki Matsumae, Takahiro Kodama, Yuki Tahata, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
December 12, 2022
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis
Yuki Tahata, Ryotaro Sakamori, Kazuki Maesaka, et al.
Scientific Reports
|
January 31, 2017
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment
Yugo Kai, Hayato Hikita, Naoki Morishita, et al.
Journal of Gastroenterology
|
September 15, 2012
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines
Naoki Harada, Naoki Hiramatsu, Tsugiko Oze, et al.
Digestive Diseases and Sciences
|
December 16, 2022
Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
June 24, 2022
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 6, 2016
Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection
Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, et al.
BMC Gastroenterology
|
May 1, 2026
Improvement of hepatic reserve and changes in liver and spleen volume after balloon-occluded retrograde transvenous obliteration
Kazuma Shinkai, Ryotaro Sakamori, Ryoko Yamada, et al.
Page
of 9